secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001641172-25-015401
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma announces Ketamir-2 publication, Phase 1 progress, SKNY acquisition update
--------------------------------------------------------------------------------

- Ketamir-2 accepted for publication in Frontiers in Pharmacology; highlights selective NMDA antagonism, no hyperlocomotion, improved oral bioavailability.
- Phase 1 trial advancing as planned with dose escalation ongoing; no reported safety concerns.
- Phase 2a trial in neuropathic pain expected to initiate by year-end 2025, pending regulatory clearance.
- Acquisition of SKNY Pharmaceuticals (including SKNY-1 for obesity/smoking cessation) progressing; SEC filings submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225015401/0001641172-25-015401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225015401/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer